Glibenclamide dose response in patients with septic shock: Effects on norepinephrine requirements, cardiopulmonary performance, and global oxygen transport

Shock

Volumn 28, Issue 5, 2007, Pages 530-535

  Morelli, Andrea ^a,e   Lange, Matthias ^b   Ertmer, Christian ^b   Broeking, Katrin ^b   Van Aken, Hugo ^b   Orecchioni, Alessandra ^a   Rocco, Monica ^a   Bachetoni, Alessandra ^a   Traber, Daniel L ^c   Landoni, Giovanni ^d   Pietropaoli, Paolo ^a   Westphal, Martin ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e NONE   (Italy)

Author keywords

Adenosine triphosphate sensitive potassium channel inhibition; Glibenclamide; Sepsis; Septic shock; Systemic inflammatory response syndrome

Indexed keywords

ELECTROLYTE; GLIBENCLAMIDE; NORADRENALIN;

AGED; ARTICLE; CARDIOPULMONARY FUNCTION; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GAS EXCHANGE; GLUCOSE BLOOD LEVEL; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; MALE; OXYGEN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK;

ADENOSINE TRIPHOSPHATE; AGED; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTENSION; LACTIC ACID; LUNG; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NOREPINEPHRINE; OXYGEN; PILOT PROJECTS; POTASSIUM CHANNELS; PULMONARY GAS EXCHANGE; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS; WATER-ELECTROLYTE BALANCE;

EID: 37349088118     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e3180556a3c     Document Type: Article

References (32)

1. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280-287, 1989.
2. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parrat JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 259:H1038-H1043, 1990.
3. Thiermann C: The role of L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 28:45-79, 1994.
4. Thiermann C: Nitric oxide and septic shock. Gen Pharmacol 29:159-166, 1997.
5. Cirino G, Sorrentino R, Cicala C, Sorrentino L, Pinto A: Indomethacin and thromboxane A2/prostaglandin H2 antagonist SQ29,548 impair in vitro contractions of aortic rings of ex-vivo treated lipopolysaccharide rats. J Lipid Mediat Cell Signal 13:177-187, 1996.
6. Bishop-Bailey D, Larkin SW, Warner TD, Chen G, Mitchell JA: Characterization of the induction of nitric oxide synthethase and cyclo-oxygenase in rat aorta in organ culture. Br J Pharmacol 131:125-133, 1997.
7. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122-1125, 1997.
8. Brackett DJ, Schaefer CF, Wilson MF: The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv Shock Res 9:147-156, 1983.
9. ATP channels in sepsis. Cardiovasc Res 72:220-230, 2006.
10. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595, 2001.
11. + channel mediates hypotension in endotoxemia andhypoxic lactic acidosis in dog. J Clin Invest 89:2071-2074, 1992.
12. ATP-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 272:H688-H694, 1997.
13. + channels. Biochim Biophys Acta 1461:285-305, 1999.
14. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 49(10 suppl 2):3-6, 2000.
15. Vanelli G, Hussain SNA, Aguggini G: Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 80:167-170, 1995.
16. Vanelli G, Hussain SNA, Dimori M, Aguggini G: Cardiovascular responses to glibenclamide during endotoxaemia in the pig. Vet Res Commun 21:187-200, 1997.
17. Gardiner SM, Kemp PA, March JE, Bennet T: Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide. Br J Pharmacol 128:1772-1778, 1999.
18. Lange M, Szabo B, Van Aken H, Williams W, Traber DL, Daudel F, Broeking K, Salzman AL, Bone HG, Westphal M: Short-time effects of glipizide (an ATP-sensitive potassium channel inhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 26:516-521, 2006.
19. Lange M, Williams W, Bone HG, Van Aken H, Broeking K, Morelli A, Hucklenbruch C, Daudel F, Ertmer C, Stubbe H, et al.: Continuously infused glipizide reverses the hyperdynamic circulation in ovine endotoxemia. Shock 27:701-706, 2007.
20. Warrillow S, Egi M, Bellomo R: Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 34:980-985, 2006.
21. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-1655, 1992.
22. Zhao KS, Huang X, Liu J, Huang Q, Jin C, Jiang Y, Zhao G: New approach to treatment of shock: restitution of vasoreactivity. Shock 18:189-192, 2002.
23. Sorrentino R, Bianca R, Lippolis S, Sorrentino L, Autore G, Pinto A: Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. Br J Pharmacol 127:1447-1453, 1999.
24. Singer M, Coluzzi F, O'Brien AJ, Clapp LH: Reversal of life-threatening, drug related potassium channel syndrome by glibenclamide. Lancet 365:1873-1875, 2005.
25. Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P: In vivo evidence for nitric oxide-mediated calcium-activated potassium-channel activation during human endotoxemia. Circulation 114:414-421, 2006.
26. Quast U, Stephan D, Bieger S, Russ U: The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 53(suppl 3):156-164, 2004.
27. ATP channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. Br J Pharmacol 144:367-375, 2005.
28. Presier JC, Zhang H, Debelle F, Fesler P, Abdel Kafi S, Naeije R, Vincent JL: Hemodynamic effects of glibenclamide during endotoxemia: contrasting findings in vitro versus in vivo. Shock 19:223-228, 2003.
29. Ashcroft FM: Adenosine 5′-triphosphate-sensitive potassium channels. Annu Rev Neurosci 11:97-118, 1988.
30. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001.
31. Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963, 1993.
32. Luckner G, Dünser MW, Jochberger S, Mayr V, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, et al.: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 33:2659-2666, 2005.